ArticleDiscover oncology2026
A nomogram-based prediction model for assessing the risk of vain and stump cancer recurrence following radical surgery for cervical cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to construct a nomogram model to predict the risk of recurrent Vaginal Stump lesions after radical Cervical Cancer (CC) surgery, including Vaginal Intraepithelial Neoplasia (VaIN) and Stump Carcinoma. 79 patients were selected from January 2013 to November 2024, and the patient information and follow-ups were retrospectively analyzed. Branched-strand DNA hybrid capture technology was performed to analyze the expression level of HPV E6/E7 mRNA. Univariate/multivariate Cox hazards regression analyses were used to identify risk factors for recurrence, in order to develop nomograms for predicting the recurrence. The clinical usefulness of the predictive models was determined through Receiver Operating Characteristic (ROC) curve. VaIN and Stump Cancer occurred in 21 (26.6%) among 79 patients with radical treatment of CC (VaIN1 = 12, VaIN2-3 = 4, Cancer = 5), and the positive expression rate of HPV E6/E7 mRNA in relapsed patients was significantly higher than that in non-relapsed patients (P < 0.05). Cox regression analysis identified these independent risk factors for recurrence: invasion of cervical canal, tumor width, HPV E6/E7 mRNA expression. The nomogram constructed by these factors demonstrated good predictive ability, with an Area Under the Curve (AUC) of 0.852 (95% CI 0.806–0.899). The calibration chart showed that the predicted values agreed well with the measured values on the nomogram. We developed and validated a nomogram based on HPV E6/E7 mRNA and clinical characteristics, which could help to screen patients at high risk for vaginal stump recurrence after cervical cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.